Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 04, 2015 1:38 AM ET

Pharmaceuticals

Company Overview of Iroko Pharmaceuticals Inc.

Company Overview

Iroko Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the development and commercialization of nonsteroidal anti-inflammatory drug therapeutics for patients to moderate acute and chronic pain. It provides Indocin for the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder, and acute gouty arthritis; and Aldomet to treat hypertension. The company’s products under development include Zorvolex, a formulation of diclofenac to treat acute pain in adult patients, as well as completed the Phase III clinical trials for the treatment of osteoarthritis pain; Tiforbex, a formulation of indomethacin that has completed the Phase III clini...

One Kew Place

150 Rouse Boulevard

Philadelphia, PA 19112

United States

Founded in 2012

71 Employees

Phone:

267-546-3003

Fax:

267-546-3004

Key Executives for Iroko Pharmaceuticals Inc.

Executive Chairman of the Board and Chief Executive Officer
Age: 53
Senior Vice President and Chief Financial Officer
Age: 68
Senior Vice President and General Counsel
Age: 48
Senior Vice President and Chief Medical Officer
Age: 59
Senior Vice President of Corporate Development and Alliance Management
Age: 55
Compensation as of Fiscal Year 2015.

Iroko Pharmaceuticals Inc. Key Developments

Iroko Pharmaceuticals Inc. Enters into Licensing Agreement with Laboratorios Saval S.A

Iroko Pharmaceuticals Inc. announced that it has entered into a licensing agreement with LABORATORIOS SAVAL S.A. for the exclusive rights to market and sell ZORVOLEX® (diclofenac) capsules, in an additional five countries in South America. LABORATORIOS SAVAL S.A. will be responsible for obtaining regulatory and pricing approval as well as provide marketing and distribution in Bolivia, Chile, Ecuador, Paraguay and Peru.

Iroko Pharmaceuticals Inc. Announces First International Launch of ZORVOLEX

Iroko Pharmaceuticals Inc. announced that ZORVOLEX (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), is now available in 18 mg and 35 mg dosage strengths by prescription in Lebanon. ZORVOLEX was approved by the Republic of Lebanon Ministry of Public Health (MOPH) as a new chemical entity in December 2014 for the treatment of mild to moderate acute pain in adults and osteoarthritis pain. ZORVOLEX is approved by the U.S. Food and Drug Administration (FDA) for the management of mild to moderate acute and osteoarthritis pain, and is available at pharmacies across the United States. Iroko Pharmaceuticals, LLC, an affiliate of Iroko Pharmaceuticals Inc., will continue to retain all marketing rights to ZORVOLEX in the U.S. ZORVOLEX was developed to align with recommendations from FDA and several professional medical organizations that NSAIDs be used at the lowest effective dose for the shortest possible duration consistent with individual patient treatment goals. ZORVOLEX is the first FDA-approved low dose NSAID developed using proprietary SoluMatrix Fine Particle Technology and is now available by prescription. ZORVOLEX contains diclofenac as submicron particles that are approximately 10 times smaller than their original size. The reduction in particle size provides an increased surface area, leading to faster dissolution.

Iroko Pharmaceuticals Inc. Announces Additional International Licensing Agreement for ZORVOLEX

Iroko Pharmaceuticals Inc. announced the initiation of a licensing agreement with Litha Pharma Proprietary Limited for the exclusive rights to market and sell ZORVOLEX (diclofenac) capsules in specified countries in East and Southern Africa. Litha will be responsible for obtaining regulatory and pricing approval as well as provide marketing and distribution in countries including Angola, Botswana, Lesotho, Madagascar, Malawi, Mauritius, Mozambique, Namibia, Republic of South Africa, Seychelles, Swaziland, Tanzania and Zambia. ZORVOLEX is approved by the United States Food and Drug Administration (FDA) for the management of mild to moderate acute pain and osteoarthritis pain, and is available at pharmacies across the United States. ZORVOLEX was also recently approved by the Republic of Lebanon Ministry of Public Health (MOPH) for these indications.

Similar Private Companies By Industry

Company Name Region
Life Extension, Inc. United States
Gencor Nutrients, Inc. United States
Geneva Pharmaceuticals Technology Corporation United States
Forbes Medi-Tech (Research) Inc. United States
The Elations Company, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Iroko Pharmaceuticals Inc., please visit www.iroko.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.